Axsome Therapeutics, Inc. $AXSM Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC raised its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 144.6% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,729 shares of the company’s stock after purchasing an additional 3,978 shares during the period. SG Americas Securities LLC’s holdings in Axsome Therapeutics were worth $702,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Axsome Therapeutics in the first quarter valued at approximately $5,843,000. Avantax Advisory Services Inc. acquired a new stake in Axsome Therapeutics during the first quarter worth approximately $246,000. Assetmark Inc. grew its stake in Axsome Therapeutics by 61.5% in the 1st quarter. Assetmark Inc. now owns 987 shares of the company’s stock worth $115,000 after acquiring an additional 376 shares during the period. TD Asset Management Inc purchased a new stake in Axsome Therapeutics in the 1st quarter worth approximately $1,048,000. Finally, Mackenzie Financial Corp acquired a new position in Axsome Therapeutics in the 1st quarter valued at $273,000. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Price Performance

AXSM stock opened at $151.20 on Tuesday. The company has a market cap of $7.62 billion, a PE ratio of -29.82 and a beta of 0.50. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. The stock has a 50-day moving average price of $129.22 and a two-hundred day moving average price of $116.32. Axsome Therapeutics, Inc. has a 12-month low of $75.56 and a 12-month high of $151.38.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The firm had revenue of $170.99 million during the quarter, compared to analyst estimates of $162.96 million. The firm’s quarterly revenue was up 63.2% on a year-over-year basis. As a group, research analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Activity at Axsome Therapeutics

In other Axsome Therapeutics news, CEO Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $132.34, for a total transaction of $12,136,239.70. Following the transaction, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $956,685.86. The trade was a 92.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Roger Jeffs sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $121.60, for a total transaction of $2,432,000.00. Following the sale, the director owned 90,974 shares of the company’s stock, valued at approximately $11,062,438.40. This represents a 18.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 370,577 shares of company stock worth $46,235,199. Company insiders own 22.30% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. B. Riley began coverage on Axsome Therapeutics in a report on Wednesday, October 1st. They set a “buy” rating and a $179.00 price objective on the stock. Bank of America increased their target price on Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a research report on Tuesday, August 5th. Wells Fargo & Company decreased their price target on Axsome Therapeutics from $163.00 to $157.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 4th. Royal Bank Of Canada lifted their price target on Axsome Therapeutics from $189.00 to $198.00 and gave the company an “outperform” rating in a report on Tuesday, November 4th. Finally, HC Wainwright upped their price objective on shares of Axsome Therapeutics from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Axsome Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $179.88.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.